ARDT · Ardent Health, Inc.

Track ARDT — free

$10.48 -0.14 (-1.32%) At close · Aug 20

Market Cap

$1.48B

141.05M

Up next

Next earnings call

Nov 8, 2026 Est · unconfirmed · in 11 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 10, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Very Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +9%

above

Price vs 50-day avg +2%

above

RSI (14) 45

neutral

MACD trend Negative

52-week position 36%

mid-range

Momentum

relative strength

Strong

1-month return +1%

trailing

6-month return +12%

trailing

YTD return +19%

this year

Relative strength 0%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +23 funds added

Insider flow Accumulating

Net +$186.4K over 90 days · 0% sells

Short interest Falling

3.06% of float · ▼ -6.3% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

138 holders — near 2-yr high, broad support

Squeeze score 54

elevated · 0–100

Fundamentals

Fair

Revenue growth +6%

Y/Y

EPS growth −39%

Y/Y

Valuation P/E 19.1

in line

Buyback $34.0M

remaining

Balance sheet $389.6M

net debt

Quant / Vol

risk profile

Very High

Volatility 54%

annualized · 1-yr

Max drawdown −49%

past year

ATR 4.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 4, 2026

Total revenue · Full Year 2026 Initiated $6.4B – $6.7B

prior FY $6.32B midpoint +3.6% Y/Y

Adjusted EBITDA · Full Year 2026 Non-GAAP Initiated $485M – $535M

Diluted earnings per share · Full Year 2026 Initiated $0.78 – $1.15

prior FY $0.96 midpoint +0.5% Y/Y

Adjusted admissions growth · Full Year 2026 Initiated 1.5% – 2.5%

Prior guidance period ended · from the 8-K filed Nov 12, 2025

Diluted earnings per share · Full Year 2025 $0.85 – $1.03

Net patient service revenue per adjusted admission growth · Full Year 2025 2.1% – 4.4%

Guided vs delivered · last 1 settled

Diluted earnings per share Full Year 2025

guided $0.85 – $1.03

guided $0.85 – $1.03 $0.96 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+9% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

45 Neutral

MACD trend

Negative Bearish

52-week position

36% Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $10 › 200d $10 — 50d above 200d

Institutional flow Accumulating

+1% holders QoQ · +23 funds added

Insider flow Accumulating

Net +$186.4K over 90 days · 0% sells

Short interest Falling

3.06% of float · ▼ -6.3% MoM · 8.0 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

138 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $8 Now $10 · 36% Range high $15

vs 200-day avg +9% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Adjusted admissions	175,570	Six Months Ended June 30, 2026	—

Adjusted EBITDA non-GAAP	$238.94M	Six Months Ended June 30, 2026	—

Adjusted EBITDA margin non-GAAP	7.4%	Six Months Ended June 30, 2026	—
Adjusted EBITDAR non-GAAP	$322.07M	Six Months Ended June 30, 2026	—

Admissions	82,036	Six Months Ended June 30, 2026	—

Average length of stay	4.71	Six Months Ended June 30, 2026	—
Emergency room visits	313,064	Six Months Ended June 30, 2026	—

Hospitals operated (at period end)	30	Six Months Ended June 30, 2026	—
Inpatient surgeries	18,362	Six Months Ended June 30, 2026	—

Licensed beds (at period end)	4,281	Six Months Ended June 30, 2026	—
Net patient service revenue per adjusted admission	$18,111	Six Months Ended June 30, 2026	—

Outpatient surgeries	44,735	Six Months Ended June 30, 2026	—

Patient days	386,352	Six Months Ended June 30, 2026	—
Total encounters	3,145,321	Six Months Ended June 30, 2026	—
Total surgeries	63,097	Six Months Ended June 30, 2026	—

Utilization of licensed beds	50%	Six Months Ended June 30, 2026	—
Lease-adjusted net leverage ratio	2.6	as of March 31, 2026	—
Net leverage ratio non-GAAP	0.8	as of December 31, 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARDT Ardent Health, Inc. this stock	$1.48B	+18.7%	+6.0%	19.1	3.1%
HCA HCA Healthcare, Inc.	$90.30B	-13.0%	+7.1%	14.0	2.7%
FSNUY Fresenius SE & Co. KGaA	$30.84B	-4.8%	—	—	0.0%
THC Tenet Healthcare Corp	$21.98B	+37.2%	+0.9%	10.5	4.0%
FMS Fresenius Medical Care AG	$12.69B	-1.6%	+5.9%	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

138

% held: 76.9%
Net QoQ: +1.6M sh
Top holder: CHAI TRUST CO LLC

Held Float

View

Held by Funds

Fund positions

136

View

Short & Settlement

Short Interest Falling

Shares short

4.3M

Days to cover: 8.0d
Change: -290.7K sh

View

Short Volume

Short vol %

34%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

1.4K

Value: $15.7K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

33.9%

Week of: Jul 13, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$186.4K

Buyers / Sellers: 2 / 0

Buyers Sellers

View

Financials

Revenue (FY)

$6.3B

Net income (FY): $135.8M
EPS diluted: $0.96

View

Buybacks

Remaining

$34.0M

View

Filings

SEC Filings

Latest

10-Q

Filed: Aug 10, 2026
This year: 12

View

Proposed Sales

Value

$377.4K

Shares: 35.9K
Filed: Aug 20, 2026

View

Earnings & Events

Earnings Calls

Last call

Aug 5, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ARDT	-4.9%	+0.6%	+11.6%	-1.8%	+18.7%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	-2.9%	-2.7%	+0.4%	-3.9%	+6.9%

Capital returns

Buyback program · as of Jun 30, 2026

Authorized

—

Spent (derived)

—

Remaining

$34.00M

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1756655 CUSIP 03980N107 13F (30d) 131 filings 130 filers Visit website Investor relations

ARDT · Ardent Health, Inc.

Price & Indicators

Up next

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns